OSRH News & Events

OSR Holdings received written notification from The Nasdaq Stock Market LLC granting the Company an additional 180-calendar-day extension to regain compliance with Nasdaq Listing Rule 5550(a)(2), the minimum $1.00 bid price requirement for continued listing on the Nasdaq Capital Market. The extension provides the Company until August 31, 2026, to satisfy the rule by achieving a closing bid price of at least $1.00 per share for ten consecutive business days. There is no immediate effect on the listing or trading of the Company's common stock, which will continue to trade on the Nasdaq Capital Market under the ticker symbol "OSRH." As outlined in the CEO's February 2026 Statement to Shareholders, the Company remains focused on strengthening its capital structure and advancing near-term value catalysts, including: VXM01 Licensing Initiative: Subsidiary Vaximm AG continues to advance discussions toward a global licensing transaction for lead immuno-oncology asset VXM01, structured to include $30M in upfront consideration and up $815M in milestone payments. Medical Device Platform Merger: Progressing consolidation of RMC and Woori IO to form an integrated medical technology and distribution platform, while advancing international partnership interest in Woori IO's non-invasive glucose monitoring technology. In its prior disclosure regarding the minimum bid price deficiency, the Company noted unusual trading dynamics impacting its share price. While management continues to monitor market activity and safeguard shareholder interests, the Company believes that disciplined execution of its strategic initiatives and continued strengthening of underlying fundamentals represent the most effective path to enhancing long-term shareholder value.

In a letter to shareholders, CEO Kuk Hyoun Hwang said, in part, "As the compliance deadline under the minimum bid requirement of NASDAQ approaches, we recognize that market volatility and uncertainty can weigh on investor sentiment. Periods like this often test confidence, particularly for innovation-driven companies that are building long-term value rather than optimizing for short-term optics. I want to take this opportunity to reaffirm that the fundamentals of OSR Holdings. remain strong, and that the management team is firmly focused on executing against clearly defined value-creating milestones. Our Swiss biotech subsidiary, Vaximm, continues to make solid progress toward finalizing the global licensing transaction for its lead asset, VXM01. Based on the Binding Term Sheet recently executed with BCM Europe, the contemplated transaction structure includes: Up to $815M in development, regulatory, and commercial milestones $30M upfront consideration, consisting of $15M in cash and $15M in digital assets While the definitive agreement remains subject to customary conditions, diligence, and final documentation, discussions are advancing constructively and in line with the economic framework already disclosed. We view this potential licensing transaction as a meaningful validation of VXM01's platform value and of OSR Holdings' hub-and-spoke biotech strategy. In parallel, we are encouraged by the ongoing strategic discussions between our two medical device subsidiaries, RMC and Woori IO. Management teams from both companies are actively working toward a potential term sheet for a merger of the two entities. The strategic rationale for this combination has strengthened further in light of recent regulatory clarity from the U.S. Food and Drug Administration regarding the oversight of non-medical-grade consumer wearable devices. This clarification enables Woori IO to pursue a dual-track commercialization strategy: Consumer wearable products positioned as lifestyle and wellness management tools, which may be commercialized independently of medical-device regulatory approvals Medical-grade non-invasive continuous glucose monitoring devices, which will continue to progress through the appropriate regulatory pathways As a result of this improved regulatory visibility, Woori IO has recently begun receiving proactive inbound interest from global device distributors, including potential partners prepared to act as importers and local agencies across key international markets. The company aims to announce formal distribution engagements in due course. When combined with RMC's established, cash-flow-generating operating platform, we believe Woori IO's differentiated technology and expanded commercial optionality create a compelling foundation for growth. Upon consummation of such merger, the combined entity will be evaluated with a view toward a Korean listing, with consideration given to the growth-oriented KOSDAQ market which has recently reached its highest index level in approximately 25 years. OSR Holdings was built to create value through disciplined capital allocation, strategic partnerships, and the maturation of differentiated healthcare technologies. Short-term market dynamics do not change that mission, nor do they alter the intrinsic value we believe is being created across our portfolio."

OSR Holdings announced the official closing of its acquisition of Woori IO, the reaffirmation of long-term equity alignment by Woori IO's historical shareholders, and the initiation of a strategic review regarding a potential combination of its medical device subsidiaries. OSRH confirmed that the previously announced acquisition of Woori IO and the related share exchange transaction have been formally completed in Korea, effective January 26, 2026. As a result, Woori IO is now a consolidated subsidiary of OSRH, further strengthening the Company's medical device and digital health platform, particularly in noninvasive glucose monitoring and wearable health technologies. In connection with the closing, historical shareholders of Woori IO reaffirmed a three-year equity alignment framework, under which they have agreed to exchange their equity interests in OSR Holdings Co., into NASDAQ-listed OSRH common stock only at a reference price of $10.00 per share. This voluntary structure is designed to prevent near-term dilution and align legacy shareholders with the long-term performance of OSRH's public equity, reflecting confidence in the Company's strategic direction and capital markets positioning. Separately, Peter Hwang, CEO of OSRH, indicated that the Company is conducting a strategic review of a potential combination of its two medical device subsidiaries, Woori IO and RMC, with the goal of forming a new, integrated medical technology and distribution company. The review reflects the complementary strengths of the two businesses, including Woori IO's digital health and wearable-device capabilities, supported by collaboration initiatives with Samsung Electronics, along with RMC's established hospital network in Korea and commercial revenue history. OSRH is evaluating whether a combined platform could support a standalone IPO in Korea, subject to market conditions, regulatory considerations, and board approvals.

OSR Holdings announced that the shareholders of Woori IO approved a share exchange at an Extraordinary General Meeting held at Woori IO's headquarters in Jeonju, Korea. The approved share exchange will result in Woori IO becoming a wholly-owned subsidiary of OSR Holdings Co. Upon completion of the share exchange, Woori IO will become a wholly-owned subsidiary of OSRK, marking the final step in a sequence of corporate actions designed to integrate Woori IO fully into the OSR Group ecosystem. Woori IO is currently collaborating with Samsung Electronics on a Proof-of-Concept study in South Korea aimed at achieving Korean regulatory approval for its breakthrough noninvasive blood glucose monitoring platform. With the corporate combination now finalized, Woori IO also plans to initiate U.S. market development activities, supported by an invitation from a prestigious research university to collaborate on a U.S. FDA clinical trial for Woori IO's technology. This collaboration is expected to serve as a foundation for advancing Woori IO's regulatory and commercial strategy in the United States.